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Objective: The activity of the renin-angiotensin system may be important in
determining the performance of coronary artery bypass grafts. We have
examined the activity of tissue angiotensin-converting enzyme and the
effects of angiotensin II in vessels used as bypass grafts. Methods: Organ
bath studies were used to determine the vasoactive effect of angiotensin II.
The activity of the angiotensin-converting enzyme was assessed by metab-
olism of a specific synthetic substrate. Results: The saphenous vein pro-
duced greater maximum responses to angiotensin II than did the internal
thoracic artery. This response was not modified by inhibition of nitric oxide
synthase, cyclooxygenase, or by an endothelin receptor antagonist in either
vessel. Losartan, an AT1 receptor antagonist, inhibited the vasoconstrictor
response in both blood vessels. Homogenates of saphenous vein and
internal thoracic artery displayed tissue angiotensin-converting enzyme
activity, which was inhibited by captopril. Enzyme activity was threefold
greater in the vein. Both the contractile response to angiotensin II and the
enzyme activity were retained in venous grafts removed up to 20 years after
coronary bypass surgery. Conclusions: These data demonstrate that marked
differences exist in angiotensin-converting enzyme activity and AT1 receptor
responses in the saphenous vein compared with the internal thoracic
artery. These findings may have important implications for the perfor-
mance of the vein when used as a coronary artery bypass graft and may
have clinical implications for the use of angiotensin-converting inhibitors
and AT1 receptor antagonists in the prevention and treatment of vein graft
disease. (J Thorac Cardiovasc Surg 1998;116:206-12)
Coronary artery bypass grafting offers patientswith ischemic heart disease a significant im-
provement in quality of life and longevity. However,
these clinical benefits are gradually lost and deteri-
oration of graft function results in recurrence of
clinical symptoms.1 The limitation of coronary ar-
tery operations is widely attributed to the poor
performance of the saphenous vein (SV) when used
as a bypass conduit.2
Morphologic changes develop in the vessel wall as
a result of loss of endothelium-derived mediators
and stimulation of smooth muscle cell growth and
contraction, resulting in deterioration of the func-
tion of the graft and its eventual failure.3 Many of
these changes have the capacity to be mediated by
angiotensin II. Animal models of atherosclerosis
and bypass grafting have demonstrated the clinical
benefits of angiotensin-converting enzyme (ACE)
inhibitors to improve the prognosis of patients with
left ventricular dysfunction, as well as to reduce
smooth muscle cell proliferation and improve endo-
thelial function in grafted vessels.4-6
Differences in the biologic properties of smooth
muscle cells and endothelial cells between the SV
and the internal thoracic artery (ITA) may influence
the regulation of vessel tone and the control of
intimal smooth muscle cell growth.7 SV graft func-
tion is inferior to that of the ITA, possibly because
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of specific differences in receptors on smooth muscle
cells, the release of endothelium-derived relaxing
factors, the actions of mitogens, and the response of
the vessel wall to mechanical trauma.8-10 The re-
sponses of endothelial and smooth muscle cells to
local ACE and angiotensin II release may influence
their differing abilities to perform as bypass con-
duits.
The involvement of angiotensin II in these patho-
physiologic processes remains largely unexplored
and requires investigation. Thus we have examined
the local tissue ACE activity, as well as the response
of the vessel wall to angiotensin II.
Methods
Undistended SVs (n 5 44), ITAs (n 5 41), and old vein
grafts, (old SVs, n 5 22) were obtained from patients
(aged 40 to 78 years, 87 male and 20 female) undergoing
coronary artery bypass grafting or cardiac transplantation.
Vessel specimens were immediately placed in Hanks
balanced salt solution or frozen in liquid nitrogen for
ACE activity studies or immunohistochemical staining of
the endothelium. All patients from whom samples were
obtained were receiving a number of different drug com-
binations. Only 17% of patients were prescribed ACE
inhibitor therapy prior to surgery, while no patient had
received an AT1 receptor antagonist. No difference in
ACE activity or angiotensin II response was seen in those
patients receiving ACE inhibitors.
Determination of tissue ACE activity. ACE activity was
determined in frozen samples of vessel specimens by
measurement of the conversion of 3H-benzoyl-phenylala-
nine-alanine-proline (3H-BPAP) a synthetic substrate for
ACE.11 The 3H-BPAP is broken down by ACE in the
tissue homogenate to 3H-benzoyl-phenyl and alanine-
proline. The tritiated product was separated from the
unchanged substrate by its dissolution into a toluene-
containing solution. The extracted 3H-BPAP product was
then assayed by liquid scintillation counting. ACE activity
was measured in the presence and the absence of the ACE
inhibitor captopril (10–6 mol/L) and expressed as units of
activity per milligram of wet weight of tissue. Results were
expressed as the mean 6 standard error of the mean and
the 95% confidence interval (CI).
In vitro organ bath studies. Isolated vessels were
mounted in organ baths containing modified Tyrode’s
solution composed of (mmol/L) 136.9 NaCl, 11.9
NaHCO3, 2.7 KCl, 0.4 NaH2PO4, 2.5 MgCl2, 2.5 CaCl2,
11.1 glucose, and 0.04 disodium ethylenediaminetetraace-
tic acid (BDH, Poole, United Kingdom). Vessel segments
were stretched to their optimum tension for smooth
muscle contractility. The vasoactive effect of angiotensin
II (Sigma, Poole, United Kingdom) was assessed by the
addition of cumulative concentrations of the peptide
(10–10 z 10–6 mol/L) in half log10 units. The means of the
absolute responses were expressed in millinewtons (mN)
6 standard error of the mean and the 95% CI.
To examine the receptor subtypes responsible for the
effects mediated by angiotensin II, vessel segments of both
Fig. 1. Measurements of ACE activity in human SVs
(n 5 25), ITAs (n 5 27), and old SVs (n 5 16). Values are
means 6 standard error of the mean. **p , 0.001 in the
SV and old SV when compared with the ITA.
Fig. 2. Contractile effect of angiotensin II in isolated
segments of SV (n, n 5 18), ITA (l, n 5 16), and old SV
(, n 5 9) bypass grafts. Values are means 6 standard
error of the mean. *p 5 0.004 in the SV when compared
with the ITA and p 5 0.03 in the SV compared with the
old SV graft.
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SV and ITA were incubated for 30 minutes with one of
three concentrations of either the AT1 receptor antago-
nist losartan (10–8, 10–7, and 10–6 mol/L) (gift from
Merck, Rahway, N.J.) or the AT2 receptor antagonist
PD123319 (10–8, 10–7, and 10–6 mol/L) (gift from Parke
Davis, Ann Arbor, Mich.) before the addition of angio-
tensin II.12 Comparative responses between the blood
vessels were made by expressing the maximum constric-
tions as a percentage of the response to a 90 mmol/L
concentration of KCl. Results were expressed as mean 6
standard error of the mean.
The contribution of endothelium-derived vasoactive
substances was assessed with prior incubation of the vessel
segments for 30 minutes with either the nitric oxide
synthase inhibitor, NG-monomethyl-L-arginine (L-NMMA)
(10–4 mol/L) (gift from Dr. S. Moncada, UCL, London,
United Kingdom), the cyclooxygenase inhibitor indometha-
cin (INN: indometacin) (10–6 mol/L), (Sigma), or the mixed
endothelin-1 (ET-1) receptor (ETA/ETB) antagonist bosen-
tan (10–5 mol/L) (gift from RPR, Daganham, Kent, United
Kingdom). The means of the absolute responses were ex-
pressed in millinewtons 6 standard error of the mean, and
the 95% CI.
Immunohistochemistry. Frozen sections, 6 mm thick,
were cut from vessels of each of the three groups. With
the use of an immunohistochemical technique employing
streptavidin biotin peroxidase (Dako Ltd., High Wy-
combe, Bucks, United Kingdom), the vessel endothelium
was labeled with a rabbit polyclonal antibody to endothe-
lial nitric oxide synthase (eNOS) (0.001 mg/ml dilution).
eNOS antibody was purchased from Transduction Labo-
ratories, Lexington, Kentucky.
Statistics. Statistical analysis was carried out using the
Primer Statistical Program (McGraw Hill Inc., New York,
N.Y.). Control and experimental groups were compared
by means of a one-way analysis of variance followed by a
Bonferroni t test.
Results
ACE activity. Human SVs (n 5 25), ITAs (n 5
27), and old SVs (n 5 16) all displayed tissue ACE
activity (Fig. 1). The ACE activity in the SV was
significantly enhanced, 5.9 6 0.5 units/mg of wet
weight (95% CI, 4.9 to 6.9 units/mg of wet weight,
Fig. 3. Contractile effect of angiotensin II in the absence (n, n 5 6) and the presence of 10–4 mol/L L-NMMA
(l, n 5 6), 10–5 mol/L bosentan (, n 5 6), or 10–6 mol/L indomethacin (w, n 5 6) in either (A) isolated
segments of SV or (B) isolated segments of ITA. Values are means 6 standard error of the mean.
Table I. Effect of angiotensin II on maximum contractile response in the SV and ITA*
L-NMMA Indomethacin Bosentan Control
SV (nN) 51.1 6 11.8 46.0 6 11.9 39.8 6 9.4 48.2 6 13.4
95% CI (mN) 20.9–104.4 15.6–76.5 15.7–63.9 13.8–82.6
p Value .0.2 .0.2 .0.2
ITA (mN) 12.1 6 1.4 19.7 6 3.1 9.3 6 4.2 12.3 6 4.5
95% CI (mN) 8.5–15.6 11.8–27.5 24.9–21.7 4.8–19.8
p Value .0.2 .0.2 .0.2
*No significant effect compared with control segments.
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p , 0.001), in comparison with the ITA, 2.1 6 0.3
units/mg of wet weight (95% CI, 1.4 to 2.8 units/mg
of wet weight). Old SV grafts retained similar levels
of ACE activity, 6.8 6 1.5 units/mg of wet weight
(95% CI, 3.5 to 10.1 units/mg of wet weight) when
compared to the native vein. There was no correla-
tion between ACE activity and the age of the graft.
The ACE inhibitor captopril (10–6 mol/L) was able
to completely inhibit ACE activity in all vessel types.
Angiotensin II responses. Angiotensin II was ca-
pable of inducing contractions in segments of SV
(n 5 18), ITA (n 5 16), and old SV (n 5 9) (Fig. 2).
Angiotensin II was approximately sevenfold more
efficacious in the native vein than in the ITA or the
old SV graft. The maximum effects in these vessels
was in the order SV . old SV 5 ITA. The maximum
contractile effect of angiotensin II was significantly
greater in the SV, 50.6 6 11.9 mN (95% CI, 25.4 to
75.8 mN), than in the ITA, 10.3 6 2.2 mN (95% CI,
5.5 to 15.0 mN) (p 5 0.004), and old SV graft, 11.3 6
2.7 mN (95% CI, 5.2 to 17.4 mN) (p 5 0.03).
Role of endothelium-derived vasoactive factors.
There was a lack of modulating effects of nitric
oxide, prostanoids, or endothelin-1 on the response
to angiotensin II in both the SV and the ITA (Fig.
3). Compared with control segments, angiotensin II
had no significant effect on the maximum contractile
response in the SV and the ITA when incubated
with L-NMMA, indomethacin, or bosentan (Table
I).
Sections of SV and ITA displayed similar endo-
thelial coverage of the vessel shown by positive
staining for eNOS. The endothelial layer, although
present, was not continuous. There were fewer
positive staining cells for eNOS in the old SV grafts
studied (Fig. 4).
Role of AT1 and AT2 receptors. The effects me-
diated by angiotensin II could be inhibited by antag-
onism of the AT1 receptor but not the AT2 receptor.
The AT1 receptor antagonist losartan caused a
concentration-dependent rightward shift of the an-
giotensin II concentration response curve and a
marked depression in the maximum effect achieved
with increasing concentrations of the antagonist in
both the SV and the ITA (Figs. 5 and 6). In contrast,
the response to angiotensin II in both vessel types
was unaffected by incubation with the AT2 receptor
antagonist PD123319.
Discussion
This study has demonstrated that both the activity
of ACE and the contractile effect of its product,
angiotensin II, are significantly greater in the SV
than in the ITA. In addition, veins that have served
as bypass conduits for up to 20 years retain similar
levels of ACE activity when compared with the
native vein.
The SV showed a threefold greater ACE activity
than that of the ITA. This result may help explain
the findings of Yang and associates,13 who demon-
strated the ability of ACE inhibitors to significantly
augment the dilator response of bradykinin which is
inactivated by ACE, in the SV but not in the ITA.
Enhancement of tissue ACE activity via gene trans-
fer into rat carotid arteries increases vascular
smooth muscle cell hypertrophy, an effect mediated
by AT1 receptors.
14 The greater ACE activity in the
Fig. 4. Photomicrographs of cross sections of (A) SV, (B)
old SV graft, and (C) ITA, showing positive staining for
eNOS (arrows). Scale bar represents 100 mm.
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vein suggests an associated enhancement in local
angiotensin II production, which may predispose the
SV to the growth-promoting actions of this peptide.
We have also demonstrated that the SV produces
a greater maximum constriction in response to
angiotensin II when compared to the ITA. The
reduced contractile response of the ITA to angio-
tensin II may have been due to greater endothelial
protection in this vessel.15 Despite similar endothe-
lial coverage and expression of eNOS, we were
unable to enhance the degree of vasoconstriction in
segments of ITA by inhibition of nitric oxide syn-
thase or cyclooxygenase. Angiotensin II has also
been shown to be capable of promoting increased
expression of the gene for, and the release of,
endothelin-1 from vascular endothelial cells, which
could potentiate the contractile effects of angioten-
sin II.16 However, in this study we were unable to
demonstrate an association between angiotensin II
induced vasoconstriction and an effect mediated by
endothelin-1 at either ETA or ETB receptors.
We have also demonstrated that in both the ITA
Fig. 5. Contractile effect of angiotensin II in the absence (n, n 5 7) and the presence of 10–8 mol/L (l,
n 5 7), 10–7 mol/L (, n 5 7), or 10–6 mol/L (w, n 5 7) of either (A) losartan or (B) PD123319 in isolated
segments of SV. Values are means 6 standard error of the mean.
Fig. 6. Contractile effect of angiotensin II in the absence (n, n 5 4) and the presence of 10–8 mol/L (l,
n 5 4), 10–7 mol/L (, n 5 4), or 10–6 mol/L (w, n 5 4) of either (A) losartan or (B) PD123319 in isolated
segments of ITA. Values are means 6 standard error of the mean.
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and the SV, contractions to angiotensin II were
mediated via the AT1 receptor but not the AT2
receptor. The AT1 receptor is present in many
human and animal organs and on smooth muscle
cells in vascular tissues, where it generally predom-
inates over the AT2 receptor and has been shown to
be responsible for mediating the contractile and
mitogenic effects of angiotensin II.12, 17 In contrast,
the AT2 receptor is localized to specific regions of
the kidney and brain, as well as in the developing
fetus. Although studies have demonstrated a func-
tional activity associated with the AT2 receptor, a
physiologic role for these receptors has not been
adequately defined.12, 17
Many human and animal in vitro studies have
shown regional variations in the response to angio-
tensin II, which are suggested to be the result of
differences in AT1 receptor density and distribu-
tion.18, 19 Thus the difference in the ability of the
vascular smooth muscle to respond to angiotensin II
in these two blood vessels may be due to the
existence of varying receptor densities or differences
in signal transduction pathways. The precise mech-
anisms that underlie the differences in the response
of angiotensin II in these blood vessels requires
further investigation.
We have demonstrated that ACE activity is re-
tained in SV bypass grafts irrespective of the age of
the graft, despite damage to the endothelium. The
retention of ACE activity may be important, since
the progression of vein graft disease in animal
models of carotid artery bypass has been shown to
benefit from treatment with ACE inhibitors,20 which
have been shown to produce a 40% reduction in
intimal hyperplasia,21 as well as restoration of endo-
thelium-dependent relaxation to acetylcholine of
grafts.22 It has been demonstrated that local ACE
activity is increased and contractile response to
angiotensin II is enhanced in experimental models
of vein graft disease.6, 23 However, we observed a
reduction in the contractile response of angiotensin
II in old vein grafts. A generalized loss of contractile
mechanisms caused by vascular stiffness, rather than
a loss of receptor function after bypass grafting, has
been reported.24 The retention of contractile recep-
tor function and endothelial dilator mechanisms in
bypass grafts suggest that vascular tone may still be
amenable to pharmacologic regulation.24, 25 The
continued activity of ACE and subsequent produc-
tion of angiotensin II may also be important with
respect to the mitogenic and/or pro-oxidant effects
of angiotensin II.
The wall of the vein graft is exposed to both
uncontrolled stretch before grafting and pulsatile
stretch after its exposure to arterial pressures. In-
creased tension has been shown to stimulate prolif-
eration of cultured smooth muscle cells from the SV
but not the ITA.26 Furthermore, in some cell types
increased stretch can up-regulate the proliferative
effect of angiotensin II and possibly enhance the
sensitivity of the vessel wall to other growth-promot-
ing factors.27, 28 The role of ACE and angiotensin II
in smooth muscle cell growth in response to stretch
has not been addressed. While in situ, the vessel wall
of the vein graft may also be acted on either in the
short term by enhanced levels of angiotensin II
during and after cardiopulmonary bypass or in the
long term by locally released angiotensin II.6, 29
This, combined with the long-term positioning of
the SV into an arterial circulation, may allow the
effects of locally released angiotensin II to override
the control mechanisms that limit intimal smooth
muscle cell growth under normal circumstances.
In conclusion, this study has demonstrated that
the SV exhibits significantly greater angiotensin
II–mediated contractions than the ITA, with en-
hanced ACE activity, suggesting its greater potential
for development of the changes associated with graft
failure. Our findings suggest the need for a clinical
trial of ACE inhibitors and AT1 receptor antago-
nists for prevention of vein graft disease.
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